20150902-P9022101.jpg
BioChip

React ⸱ Respond ⸱ Reconnect

A small trickle brings bold advances

Our BioChip is developed to tackle difficulties in distinguishing between diseases with very similar symptoms and aid front-line professionals with making patient management decisions. This is achieved by targeting multiple diseases through a microarray.

Picture1.png
Respiratory
Diseases

Respiratory Illnesses

Global episodes and deaths attributable to lower respiratory infections in 2016 are around 300 million. Respiratory infections place a significant socioeconomic burden on individuals, families, and society. It causes illnesses that range in severity and sometimes lead to hospitalization and death. 
With our multiplex BioChip, we provide N-in-1 respiratory diseases diagnostics for SARS-CoV-2, Influenza, RSV, Streptococcus, and Adenovirus which covers 95% cases with common flu-like symptoms.

33123.png
Tropical
Disesases

Mosquito Borne Diseases (Tropical Diseases)

​​

Dengue fever is common in more than 100 countries around the world. 40% of the world’s population, about 3 billion people, live in areas with a risk of dengue. A blood test is the only way to confirm the diagnosis. 
With our ALiA platform, we provide a one-stop blood test for dengue and similar viruses like Zika or chikungunya within 15 minutes.

Couple's Feet in Bed
Sexually
Transmitted
Diseases

Sexually Transmitted Diseases 

More than 1 million sexually transmitted infections (STIs) are acquired EVERY DAY worldwide. WHO estimated 376 million new infections with 1 of 4 STIs: chlamydia (127 million), gonorrhea (87 million), syphilis (6.3 million), and trichomoniasis (156 million). 
ALiA BioChip can provide a quick screen of suspected viral infections for men and women.

Stomach Ache
surgeons-performing-operation-operation-
Sepsis

Sepsis

Rapid diagnostics of Sepsis play an important role in relieving the burden of over 10 million global cases of blood infection-related death TIME. Respiratory and diarrhea infections are the largest contributors to sepsis cases and sepsis-related mortality across all ages in 2017.

With our Sepsis BioChip, we offer a comprehensive diagnostic solution for life-threatening and time-critical infections.

Gastrointestinal
Infections

Gastrointestinal Infections

Outbreak of gastrointestinal infections (GI) is a serious concern in hospitals. Clostridium difficile infection (CDI) is a major cause of hospital-associated GI illness and creates a huge burden on the healthcare system. 
With our array-based BioChip, we provide diagnostic tests for CDI and its toxins, which can be further developed into panels distinguishing viral, bacterial, and parasite infections.

 

The ALiA® SARS-CoV-2 Antigen FIA Test employs a unique immunofluorescent-based BioChip with our advanced microfluidic and microarray technologies for the qualitative detection of nucleocapsid protein from SARS-CoV-2. The ALiA® SARS-CoV-2 Antigen FIA Test delivers a 20-minute result of direct nasopharyngeal swab from COVID-19 suspected patients with symptoms onset within 14 days.

Virus Studies
Get Multiple Results Through Our Scalable Array-Based BioChip

Benefiting from our well-established Lab-On-Chip platform (including the POC device and the Lab-On-Chip biochip), the multiplexing microarray development for different test panels (e.g. 5-in-1 respiratory virus panel) is scalable with a short period of 6-9 months for new application adaption.